The $141 million market capped development stage drug maker Synthetic Biologics, Inc. (NYSEMKT:SYN) was forced to release a public statement on 13th February, that it will not comment on any out of the ordinary spurts or dip in the value of the company stock after its stock posted close to 30 percent increase in value during trading in the past week. Synthetic Biologics Inc (NYSEMKT:SYN) stock opened at $2.76 in last session, and closed at $2.90, while the day range of SYN stock is $2.70 – $3.05. The stock showed a positive weekly performance of 9.43%.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for intravenous (i.v.) peramivir that was submitted to the FDA in December 2013. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock opened at $12.48, in last session and closed at $12.83, by gaining 10.51%. The 52 week range of BCRX is $1.12 – $13.33. Company’s market capitalization is $758.14million.
Arca Biopharma Inc (NASDAQ:ABIO) major shareholder Riley Mccormack bought 1,000,000 shares of the company’s stock on the open market in a transaction that occurred. Arca Biopharma Inc (NASDAQ:ABIO) stock advanced 6.34% and finished the last session at $1.93. The EPS of the stock remained -1.49. Company’s market capitalization is $30.25million.
Agnus Inc (NASDAQ:AGEN) announced the completion of 4-Antibody AG which is a privately held European biopharmaceutical company. With this acquisition the company took-over Retrocyte Display® technology platform which facilitates rapid discovery of human antibodies which could be effective against molecular targets of various kinds. Agenus Inc (NASDAQ:AGEN) stock opened the session at $4.19, and closed the session at $4.48. The 52 week range of the AGEN stock remained $2.40 – $5.40 and the day range was $3.96 – $4.60.